Abstract
E1-deleted adenoviral vectors are increasingly being utilized for in vivo gene transfer. The potential use of these vectors is limited by transient expression of the transgene and a markedly reduced rate of transduction following readministration, presumably due to a host immune response to the vector. We hypothesized that CD4+ lymphocytes are necessary to generate an immune response to these vectors and that administration of a depleting anti-CD4 antibody (GK1.5) might prolong transgene expression in vivo. We found that pretreatment of mice with a single injection (transient depletion) or weekly injections of GK1.5 (persistent depletion), markedly prolonged expression of an adenovirus-encoded tumor necrosis factor (TNF) inhibitor or luciferase gene compared to controls. Moreover, mice treated with GK1.5 showed no antiadenoviral antibody response to repeat administration of the vector and a second adenoviral transgene could be expressed in these animals. However, control mice developed a significant neutralizing antibody response that prevented transgene expression with administration of a second adenovirus. These findings demonstrate that manipulation of the host immune response may expand potential applications of gene transfer utilizing adenoviral vectors.
Overview summary
Adenoviral vectors elicit both a humoral antibody and cytotoxic T cell immune response that limits their effectiveness in vivo. Abrogating T cell help by transiently depleting CD4+ T cells with an anti-CD4 monoclonal antibody prior to adenovirus prevents both development of a neutralizing antibody and effective cytotoxic T cell response to the vector. Thus, in vivo transgene expression in this model is prolonged and permits repeat administration of another adenoviral vector.
Get full access to this article
View all access options for this article.
